Key result
AT1-AAs were detected in 71% of neonates born to AT1-AA positive mothers with preeclampsia, but their presence was not associated with significant differences in neonatal clinical outcomes such as birth weight or Apgar scores.
Why the study?
Maternal AT1-AAs are implicated in preeclampsia pathophysiology, but their presence in offspring and possible neonatal effects had not been specifically explored.
Does the presence of AT1-AAs in mothers with preeclampsia affect clinical outcomes in their neonates?
Observational (n=64)
No
Does the presence of AT1-AAs in mothers with preeclampsia affect clinical outcomes in their neonates?
Absolute Event Rate: 71% vs 0%
AT1-AAs cross the placenta and are detectable in neonates of mothers with preeclampsia, but their presence is not associated with immediate adverse clinical signs in the first days of life.
Neonatal AT1-AA detection shows no short-term clinical impact; leaves open longer-term effects in preeclampsia-exposed infants.
BACKGROUND: Maternal agonistic autoantibodies against the angiotensin II type 1 receptor (AT1-AAs) have been implicated in the pathophysiology of preeclampsia, but their presence in their offsprings and their possible neonatal effects have not been specifically explored. This prospective study aimed to evaluate the presence of AT1-AAs and their potential clinical effects in neonates of AT1-AAs positive mothers. METHODS: Women with preeclampsia and their neonates were included. Blood samples were collected in order to search for AT1-AAs. RESULTS: AT1-AA determination was positive in 35 out of 64 of the studied women (54.7%). Thirty one newborns from the group of AT1-AA positive women were included and 22 (71%) were AT1-AA positive. The mothers' and children's AT1-AAs titers were significantly correlated. The 33 newborns from the group of AT1-AA negative women were all negative for AT1-AAs. Regarding the clinical data of newborns (birth weight, percentile of weight, gestational age, Apgar score at five minutes, mechanical or noninvasive ventilation), no significant difference was observed between the children with or without detected AT1-AAs. CONCLUSION: Even though AT1-AAs are detected in newborns of positive mothers during the first days of life, no specific clinical signs seem to be associated with the presence of these antibodies.
No takes yet. Share an insight, caveat, or question.
Ponthier et al. (2025) conducted an observational in Preeclampsia (n=64). Maternal AT1-AA positivity vs. Maternal AT1-AA negativity was evaluated on Presence of AT1-AAs in neonates. AT1-AAs were detected in 71% of neonates born to AT1-AA positive mothers with preeclampsia, but their presence was not associated with significant differences in neonatal clinical outcomes such as birth weight or Apgar scores.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: